Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve made it to the end of the week! I don’t know about you, but it’s felt like an especially long week for me. It’s probably cause of all the news that we will get into right now.
The need-to-know this morning
- Bristol Myers Squibb reported second-quarter earnings.
EMA issues negative opinion on Leqembi
From STAT’s Andrew Joseph: European regulators said today that Leqembi, the Eisai and Biogen Alzheimer’s medicine that’s approved in the U.S. and a number of other countries, should be rejected. In its statement, the European Medicines Agency said the benefits of Leqembi did not outweigh the risks associated with its class of therapies, namely a condition called ARIA that involves brain swelling and bleeding.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect